BiondVax Pharmaceuticals has completed its first Phase II trial of Multimeric-001, its universal flu vaccine, and the results have spurred the company to begin planning its next test of the vaccine. The 200-participant study hit its primary and secondary endpoints, with good immunogenicity and safety data, including statistically significant antibody and cell-mediated immune responses.
"We have confirmed, in what is to our knowledge the first Phase II study of a universal influenza vaccine ever conducted in the world, that the Multimeric-001 vaccine is not only safe and immunogenic on its own, but it also has the potential to enhance the performance of traditional strain-dependant flu vaccines," Ron Babecoff, BiondVax's CEO, said in a release.
The Israeli company also stated that Multimeric-001, which was given in two doses during the trial, enhanced a traditional flu vaccine's performance. BiondVax's next trial of the vaccine is planned for the fourth quarter of this year and will evaluate the effects of the shot in elderly patients.
- check out the BiondVax release
- here's more from Reuters